S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NYSE:CNMD

CONMED (CNMD) Stock Price, News & Analysis

$80.80
-0.56 (-0.69%)
(As of 02/23/2024 ET)
Today's Range
$80.17
$81.33
50-Day Range
$80.93
$113.62
52-Week Range
$80.01
$138.47
Volume
324,445 shs
Average Volume
641,639 shs
Market Capitalization
$2.48 billion
P/E Ratio
39.61
Dividend Yield
0.99%
Price Target
$120.43

CONMED MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
48.7% Upside
$120.43 Price Target
Short Interest
Bearish
15.61% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
0.33mentions of CONMED in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$252,839 Sold Last Quarter
Proj. Earnings Growth
30.88%
From $4.34 to $5.68 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.86 out of 5 stars

Medical Sector

28th out of 939 stocks

Electromedical Equipment Industry

1st out of 20 stocks


CNMD stock logo

About CONMED Stock (NYSE:CNMD)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

CNMD Stock Price History

CNMD Stock News Headlines

Med-tech stock Conmed dips ahead of big Q4 report...opportunity?
Currently in the mid-$90’s, CONMED itself is in need of some restorative surgery - and this week’s earnings release could be the first step.
CNMD Mar 2024 80.000 call
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
CNMD Mar 2024 80.000 put
CNMD Mar 2024 105.000 call
CNMD Mar 2024 90.000 put
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
Cracking The Code: Understanding Analyst Reviews For Conmed
Piper Sandler Reaffirms Their Buy Rating on Conmed (CNMD)
These Analysts Revise Their Forecasts On CONMED After Q4 Results
Recap: Conmed Q4 Earnings
Here's what Wall Street expects from Conmed's earnings report
CONMED Q4 2023 Earnings Preview
Conmed's Earnings: A Preview
Here's Why You Should Retain CONMED (CNMD) Stock for Now
See More Headlines
Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/26/2023
Ex-Dividend for 1/5 Dividend
12/15/2023
Dividend Payable
1/05/2024
Today
2/23/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Employees
4,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$120.43
High Stock Price Target
$141.00
Low Stock Price Target
$98.00
Potential Upside/Downside
+48.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$64.46 million
Pretax Margin
6.49%

Debt

Sales & Book Value

Annual Sales
$1.24 billion
Cash Flow
$5.22 per share
Book Value
$24.46 per share

Miscellaneous

Free Float
28,415,000
Market Cap
$2.50 billion
Optionable
Optionable
Beta
1.39
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives















CNMD Stock Analysis - Frequently Asked Questions

Should I buy or sell CONMED stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CNMD shares.
View CNMD analyst ratings
or view top-rated stocks.

What is CONMED's stock price target for 2024?

7 equities research analysts have issued 12 month price targets for CONMED's shares. Their CNMD share price targets range from $98.00 to $141.00. On average, they expect the company's share price to reach $120.43 in the next twelve months. This suggests a possible upside of 48.7% from the stock's current price.
View analysts price targets for CNMD
or view top-rated stocks among Wall Street analysts.

How have CNMD shares performed in 2024?

CONMED's stock was trading at $109.51 at the beginning of 2024. Since then, CNMD stock has decreased by 26.1% and is now trading at $80.97.
View the best growth stocks for 2024 here
.

Are investors shorting CONMED?

CONMED saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 4,800,000 shares, an increase of 11.4% from the January 15th total of 4,310,000 shares. Based on an average trading volume of 479,900 shares, the days-to-cover ratio is currently 10.0 days.
View CONMED's Short Interest
.

When is CONMED's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our CNMD earnings forecast
.

How were CONMED's earnings last quarter?

CONMED Co. (NYSE:CNMD) issued its quarterly earnings data on Wednesday, January, 31st. The company reported $1.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.11 by $0.05. The business earned $327.05 million during the quarter, compared to analysts' expectations of $332.94 million. CONMED had a net margin of 5.18% and a trailing twelve-month return on equity of 13.95%.

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED announced a quarterly dividend on Monday, December 4th. Shareholders of record on Monday, December 18th will be paid a dividend of $0.20 per share on Friday, January 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date is Friday, December 15th.
Read our dividend analysis for CNMD
.

Is CONMED a good dividend stock?

CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.98%. The dividend payout ratio is 39.22%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CNMD will have a dividend payout ratio of 14.08% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CNMD.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY 2024 earnings guidance on Wednesday, January, 31st. The company provided earnings per share guidance of 4.300-4.400 for the period, compared to the consensus EPS estimate of 4.400. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Who are CONMED's major shareholders?

CONMED's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.12%), Capital Research Global Investors (8.97%), Dimensional Fund Advisors LP (2.32%), Principal Financial Group Inc. (1.95%), Voya Investment Management LLC (1.60%) and Jennison Associates LLC (1.12%). Insiders that own company stock include Brian Concannon, Curt R Hartman, Daniel S Jonas, John D Ferrell, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, Todd W Garner and Todd W Garner.
View institutional ownership trends
.

How do I buy shares of CONMED?

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CNMD) was last updated on 2/23/2024 by MarketBeat.com Staff